Here are the 10-K annual reports from OneMedNet Corp (ONMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ONMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONMD filings page.
OneMedNet Corporation filed Amendment No. 1 to its annual report to add updated Part III information on directors, executive officers, compensation, ownership and related-party dealings. The company reports an aggregate market value of non‑affiliate common equity of $13.8 million as of June 30, 2025 and had 52,196,729 common shares outstanding as of March 27, 2026.
The filing details 2025 executive pay, including total compensation of $1,107,622 for CEO Aaron Green and $537,848 for founder and CMO Jeffrey Yu, largely driven by restricted stock unit grants. It outlines significant insider financings, such as conversion of about $3.3 million of shareholder and extension loans into 4,693,296 shares at $0.71 per share and earlier conversion of approximately $1.66 million of PIPE Notes into 1,453,174 shares at $1.14 per share. Additional private placements with directors in 2025–2026 provided several million dollars of cash proceeds at prices between $0.42 and $0.89 per share.
OneMedNet Corporation filed its annual report describing a niche business curating regulatory-grade imaging Real World Data for life sciences customers through a federated network of more than 2,130 healthcare sites. The company remains unprofitable, with net losses of $2.8 million in 2025 and $10.1 million in 2024 and an accumulated deficit of about $104.4 million, and its auditors raised substantial doubt about its ability to continue as a going concern. Management highlights a highly regulated, competitive environment, a workforce of roughly 23 employees, and heavy reliance on data privacy, cybersecurity and FDA-quality compliance. During 2025, OneMedNet completed equity financings, insider-led subscriptions and multiple debt-for-equity conversions that together eliminated roughly $11.9 million of current liabilities, which it states equals a 62% reduction in total liabilities outstanding as of year-end 2025, while also detailing extensive regulatory, operational and market risks.